Amol Akhade: Another Negative trial for anti TIGIT drugs – KEYVIBE 008
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“Another Negative trial for anti TIGIT drugs. KEYVIBE 008. Vibostolimab plus pembrolizumab plus chemo vs atezo plus chemo.
Negative in ES-SCLC. Expected Results based upon earlier data.
It is worth to note that addition of Vibostolimab lead to increased toxicity of pembrolizumab, probably that being the reason of underperformance of pembrolizumab arm.”
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023